CPX-351: Phase III complete enrollment

Celator completed enrollment of 300 patients ages 60-75 in an open-label, North American Phase III trial comparing 100 units/m 2 IV CPX-351 on days 1, 3 and 5 vs. 100 mg/m 2/day IV cytarabine for 7 da...